Hematopoiesis News

Hematopoiesis News is an online resource that provides updates on the latest research in the fields of hematopoiesis, blood, and bone marrow disorders.

Subscribe|Follow Us On

MERTK Inhibition Selectively Activates a DC–T-Cell Axis to Provide Anti-Leukemia Immunity

September 26, 2024

[Leukemia] Host Mertk knock-out or MERTK inhibitor MRX-2843 increased CD8α+ dendritic cells with enhanced antigen-presentation capacity in the leukemia microenvironment and inhibited leukemogenesis.

Impact of Soluble BCMA and Non-T-Cell Factors on Refractoriness to BCMA-Targeting T-Cell Engagers in Multiple Myeloma

September 26, 2024

[Blood] Scientists leveraged whole genome sequencing and in vitro assays to demonstrate that soluable (s)BCMA may independently predict primary refractoriness to anti-BCMA therapies. In addition to sBCMA, tumor burden and surface BCMA antigen density collectively influence anti-BCMA TCE cytotoxic efficacy.

MERTK Inhibition Selectively Activates a DC–T Cell Axis to Provide Anti-Leukemia Immunity

September 25, 2024

[Leukemia] Scientists probed anti-leukemia immune mechanisms and evaluated roles for TYRO3 and AXL in the leukemia microenvironment. Host Mertk knock-out or MERTK inhibitor MRX-2843 increased CD8α+ dendritic cells with enhanced antigen-presentation capacity in the leukemia microenvironment and inhibited leukemogenesis.

The Present and Future for CAR-T Cell Therapy in Adult B Cell ALL

September 25, 2024

[Blood] Overall, CAR-T therapy signifies a paradigm shift in B-ALL management, with the potential for improved remission and survival in a historically challenging patient population.

Focal Deletions of a Promoter Tether Activate the IRX3 Oncogene in T Cell Acute Lymphoblastic Leukemia

September 25, 2024

[Blood] Investigators described a novel mechanism of oncogene activation whereby focal copy number loss of an intronic element within the FTO gene led to aberrant expression of IRX3, an oncogene in T cell acute lymphoblastic leukemia

Autoantibodies Neutralizing Type I IFNs Underlie Severe Tick-Borne Encephalitis in ∼10% of Patients

September 25, 2024

[Journal of Experimental Medicine] Researchers showed that ∼10% of patients hospitalized for severe tick-borne encephalitis (TBE) carried auto-Abs neutralizing IFN-α2, -β, and/or -ω at the onset of disease, contrasting with only ∼1% of patients with moderate and mild TBE.

Sirolimus Reduces T Cell Cycling, Immune Checkpoint Marker Expression, and HIV-1 DNA in People with HIV

September 25, 2024

[Cell Reports Medicine] Scientists evaluated the safety of sirolimus in people with HIV (PWH) and study the impact of sirolimus on HIV-1 reservoir size and HIV-1-specific immunity in a single-arm study of 20 weeks of treatment in PWH on antiretroviral therapy.

CXCR4 as a Therapeutic Target in Acute Myeloid Leukemia

September 24, 2024

[Leukemia] Investigators examine its molecular aspects influencing cancer progression, such as its impact on autonomous proliferation, apoptotic regulation, chemoresistance mechanisms, and interactions with non-leukemic cells such as MSCs and Treg cells.

Outcomes of Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Congenital Amegakaryocytic Thrombocytopenia; a Study on Behalf of the PDWP of the EBMT

September 24, 2024

[Bone Marrow Transplantation] In this retrospective study, scientists analyzed 66 patients with allo-hematopoietic stem cell transplantation, reported in the European Society for Blood and Marrow Transplantation registry. Bone marrow was the most widely used stem cell source followed by peripheral blood, and unrelated umbilical cord blood.

Deciphering Avian Hematopoietic Stem Cells by Surface Marker Screening and Gene Expression Profiling

September 24, 2024

[Molecular Immunology] Investigators adapted methods from mouse studies to isolate avian HSCs as lineage-negative cells. These isolated cells were further identified as Lin-Sca1+c-Kit+ and were found to be more prevalent than in control groups.

Ryvu Therapeutics Announces Dosing of the First Patient in the REMARK Phase II Study of RVU120 for the Treatment of Anemia in Patients with...

September 24, 2024

[Ryvu Therapeutics] Ryvu Therapeutics, a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, announced that the first patient has been dosed in the REMARK study, a Phase II clinical trial investigating RVU120 as a monotherapy for the treatment of patients with LR-MDS.

Cancer Council WA Award for Researcher Battling to Help Children with Leukemia

September 24, 2024

[Perth Now] A researcher at the Kids Research Institute Australia in Nedlands has been recognised by the Cancer Council WA for his work to provide better outcomes for young children with leukemia.

Hematopoiesis News curates the top publications and reviews covering the regulation, expression patterns, differentiation and characterization of hematopoietic stem cells, as well as blood and bone marrow disorders. We also feature the latest job postings and upcoming conferences in the hematopoiesis field.